ROME, ITALY — Using the factor Xa inhibitor edoxaban (Savaysa/Lixiana, Daiichi Sankyo) to anticoagulate patients about to undergo electrical cardioversion for their atrial fibrillation (AF) seems ...
A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...
A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...
Key points A 68-year-old woman from rural Ontario arrived at her local emergency department with worsening palpitations. Her medical history included breast cancer treated with surgical resection and ...
Zacks Investment Research on MSN
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Bayer AG BAYRY announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial ...
AngusWorld on MSN
Heart rocedure is the first of many for Ninewells
A cutting-edge procedure for those suffering from the heart condition atrial fibrillation has been successfully performed for ...
Bayer AG BAYRY announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback